The role of GLP-1 receptor agonists in managing type 2 diabetes
===============================================================


In the August 2022 issue, an error appeared in *Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med 2022; 89(8):[457–464](http://www.ccjm.org/lookup/doi/10.3949/ccjm.89a.21110). doi:10.3949/ccjm.89a.21110*. In Table 1, the frequency of administration of tirzepatide is once weekly, not once daily. Additional available tirzepatide doses have also been added. The corrected Table 1 appears below:

View this table:
[TABLE 1](http://www.ccjm.org/content/89/10/597/T1)

TABLE 1 
Glucagon-like peptide-1 receptor agonists approved for use in the United States

This is now correct on [ccjm.org](http://ccjm.org).

*   Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.